ArticleAdvanced functional materials2021
Foliar Delivery of siRNA Particles for Treating Viral Infections in Agricultural Grapevines.
Article in Advanced functional materials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 23 citations in OpenAlex.
- The unfulfilled potential of nanocarriers for RNA delivery in antiviral crop protection.Nature plants · 2026Review
- Control of tomato brown rugose fruit virus (ToBRFV) in tomato plants using in vivo synthesized dsRNA.Journal of experimental botany · 2026Article
- Nanoparticle-Mediated Nucleic Acid Delivery Systems in Plant Biotechnology: Recent Advances and Emerging Challenges.Plants (Basel, Switzerland) · 2025Review
- Nanoparticles and Nanocarriers for Managing Plant Viral Diseases.Plants (Basel, Switzerland) · 2025Review
- Integrating RNA Interference and Nanotechnology: A Transformative Approach in Plant Protection.Plants (Basel, Switzerland) · 2025Review
- Review
- Towards realizing nano-enabled precision delivery in plants.Nature nanotechnology · 2024Review
- Improving RNA-based crop protection through nanotechnology and insights from cross-kingdom RNA trafficking.Current opinion in plant biology · 2023Review
- Recent Progress on Nanocarriers for Topical-Mediated RNAi Strategies for Crop Protection-A Review.Molecules (Basel, Switzerland) · 2023Review
- Foliar Application of dsRNA Targeting Endogenous Potato (International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
Grapevine leafroll disease (GLD) is a globally spreading viral infection that causes major economic losses by reducing crop yield, plant longevity and berry quality, with no effective treatment. Grapevine leafroll associated virus-3 (GLRaV-3) is the most severe and prevalent GLD strain. Here, we evaluated the ability of RNA interference (RNAi), a non-GMO gene-silencing pathway, to treat GLRaV-3 in infected Cabernet Sauvignon grapevines. We synthesized lipid-modified polyethylenimine (lmPEI) as a carrier for long double-stranded RNA (dsRNA, 250-bp-long) that targets RNA polymerase and coat protein genes that are conserved in the GLRaV-3 genome. Self-assembled dsRNA-lmPEI particles, 220 nm in diameter, displayed inner ordered domains spaced 7.3±2 nm from one another, correlating to lmPEI wrapping spirally around the dsRNA. The particles effectively protected RNA from degradation by ribonucleases, and Europium-loaded particles applied to grapevine leaves were detected as far as 60-cm from the foliar application point. In three field experiments, a single dose of foliar administration knocked down GLRaV-3 titer, and multiple doses of the treatment kept the viral titer at baseline and triggered recovery of the vine and berries. This study demonstrates RNAi as a promising platform for treating viral diseases in agriculture.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.